Skip to main navigation Skip to search Skip to main content

Development of a cobalt(iii)-based ponatinib prodrug system

  • Marlene Mathuber
  • , Michael Gutmann
  • , Mery La Franca
  • , Petra Vician
  • , Anna Laemmerer
  • , Patrick Moser
  • , Bernhard K. Keppler
  • , Walter Berger (Corresponding author)
  • , Christian R. Kowol (Corresponding author)

Publications: Contribution to journalArticlePeer Reviewed

Original languageEnglish
Pages (from-to)2468-2485
Number of pages18
JournalInorganic Chemistry Frontiers
Volume8
Issue number10
DOIs
Publication statusPublished - 30 Mar 2021

Funding

We gratefully acknowledge the Austrian Science Fund (FWF) for financial support. Grant P28853 to CK and grant FG3 to WB and CK.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Austrian Fields of Science 2012

  • 104003 Inorganic chemistry
  • 301207 Pharmaceutical chemistry

Keywords

  • AP24534
  • CHRONIC MYELOID-LEUKEMIA
  • COMPLEXES
  • CYTOTOXICITY
  • HYPOXIA
  • INHIBITOR
  • NITROGEN MUSTARDS
  • PROLIFERATION
  • UP-REGULATION
  • VISUALIZATION

Fingerprint

Dive into the research topics of 'Development of a cobalt(iii)-based ponatinib prodrug system'. Together they form a unique fingerprint.

Cite this